For both in vitro and in vivo studies using patient-derived xenografts from ARID1A-deficient bladder cancer cell lines, treatment with the EZH2 inhibitor GSK-126 exhibited synergistic effects in reducing cell viability, highlighting the potential of PI3K pathway inhibitors in ARID1A-deficient bladder cancer therapy [56]. This evidence concerns the gene EZH2 and urinary bladder cancer.